Patients who will receive 40 Gy in 15 fractions to the entire breast or chest wall over three weeks and have had breast conservation surgery (BCS) or oncoplastic breast surgery(OBS) will receive an additional boost to the tumour site if and will receive sequential dose 12GY\4 fractions or SIB 8GY 15 fractions. The supraclavicular fossa will be treated in patients with node-positive disease or those who had received neoadjuvant chemotherapy . The IMLN will be irradiated in N2and N3 at first presentation.

Patients who will receive 26 Gy in 5 fractions to the entire breast and or chest wall for one week only. The volume of this arm will be the same as the volume of the control arm as regard axillary nodes, supraclavicular and IMLN. Patients who have had breast conservation or oncoplastic breast surgery(OBS) will be given a boost. If a boost is given, SIB of 6 Gy in 5 fractions will be used (or a sequential boost of 12GY\4 fractions).

Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.

Rate of acute grade 2 toxicity or higher from the treatment till 3 months (NCI_CTCAE).

Each patient will be assesed weekly during radiotherapy and monthly for 3 months post radiotherapy.

Rate of chronic toxicity grade 2 or higher ( NCI_CTCAE) from 6 months after radiotherapy up to 2 years.

Each patient will be assessed before treatment and at 6,12 and 24 months from treatment.

Rate of ipsilateral locoregional tumor recurrence proved by imaging and biopsy.

Compliance to treatment (number of interrupted days of radiotherapy.

Overall survival (Number of the surviving patients for 2 years in each arm of the study)